Log In
BCIQ
Print this Print this
 

Gelnique, oxybutynin gel 3% (Anturol, Gelnique 3%)

Also known as: Anturol Gel (AP-1034)

  Manage Alerts
Collapse Summary General Information
Company Antares Pharma Inc.
DescriptionAdvanced transdermal delivery (ATD) gel formulation of oxybutynin, a competitive antagonist of M1, M2 and M3 subtypes of the muscarinic acetylcholine receptor
Molecular Target Muscarinic acetylcholine receptor M1 (CHRM1) (HM1) ; Muscarinic acetylcholine receptor M2 (CHRM2) (HM2)
Mechanism of ActionUndisclosed
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationIncontinence
Indication DetailsTreat overactive bladder (OAB)
Regulatory Designation U.S. - Special Protocol Assessment (Treat overactive bladder (OAB))
PartnerAllergan plc;
Daewoong Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/23/2012

Undisclosed

Undisclosed

Undisclosed

07/18/2011

Undisclosed

0

Undisclosed

Get a free BioCentury trial today